Table 3 Treatment outcomes and baseline characteristics by timing of ART initiation
Variable | Timing of ART | Â | |
|---|---|---|---|
Within 7Â days, n (%) | Beyond 7Â days, n (%) | p-value | |
Sex | Â | Â | 0.055 |
 Male | 95 (52.8) | 80 (42.8) |  |
 Female | 85 (47.2) | 107 (57.2) |  |
Age group | Â | Â | 0.001* |
 0–5 | 96 (53.3) | 173 (92.5) |  |
 6–15 | 76 (42.2) | 7 (3.7) |  |
 15–18 | 8 (4.4) | 7 (3.7) |  |
Adherence on ART | Â | Â | 0.012* |
 Good adherence (≥3 consecutive clinic visits) | 65 (36.1) | 45 (24.1) |  |
 Inconsistent adherence | 115 (63.9) | 142 (75.9) |  |
Baseline Nutrition status | Â | Â | 0.020* |
 Normal limits & mild malnutrition | 83 (46.1) | 109 (58.3) |  |
 Moderate & severe malnutrition | 97 (53.9) | 78 (41.7) |  |
Baseline ART regimen | Â | Â | 0.001* |
 Nevirapine based | 45 (25.0) | 98 (52.4) |  |
 Efavirenz based | 58 (32.2) | 14 (7.5) |  |
 Protease Inhibitor based | 73 (40.6) | 62 (33.2) |  |
 Triple RTI | 4 (2.2) | 13 (7.0) |  |
WHO clinical stage | Â | Â | 0.001* |
 I & II | 52 (28.9) | 84 (44.9) |  |
 III & IV | 128 (71.1) | 103 (55.1) |  |
Treatment outcome | Â | Â | Â |
 Alive and on treatment | 141 (78.3) | 123 (65.8) | 0.026* |
 Dead | 15 (8.3) | 27 (14.4) |  |
 Lost to follow-up | 6 (3.3) | 16 (8.6) |  |
 Transferred out | 10 (10.0) | 21 (11.2) |  |